Disc Medicine, Inc. (IRON)
(Delayed Data from NSDQ)
$51.74 USD
+1.39 (2.76%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $51.75 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Income Statements
Fiscal Year end for Disc Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 91 | 47 | 69 | 1 | 0 |
Income After Depreciation & Amortization | -91 | -47 | -69 | -1 | 0 |
Non-Operating Income | 15 | 1 | -1 | 0 | NA |
Interest Expense | 0 | 0 | 2 | 0 | NA |
Pretax Income | -76 | -47 | -72 | -1 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -76 | -47 | -72 | -1 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -76 | -47 | -72 | -1 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -91 | -47 | -69 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -91 | -47 | -69 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.32 | 1.04 | 4.04 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.42 | -45.05 | -17.80 | NA | NA |
Diluted Net EPS (GAAP) | -3.42 | -45.05 | -17.80 | -0.50 | NA |
Fiscal Year end for Disc Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 30.86 | 31.46 | 29.72 | 18.96 | 17.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -30.86 | -31.46 | -29.72 | -18.96 | -17.33 |
Non-Operating Income | 4.56 | 4.52 | 6.17 | 4.86 | 1.41 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -26.29 | -26.94 | -23.55 | -14.10 | -15.92 |
Income Taxes | 0.06 | 0.01 | 0.03 | 0.02 | 0.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -26.35 | -26.95 | -23.58 | -14.12 | -15.95 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -26.35 | -26.95 | -23.58 | -14.12 | -15.95 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 25.65 | 24.81 | 24.31 | 24.32 | 21.49 |
Diluted EPS Before Non-Recurring Items | -1.03 | -1.09 | -0.97 | -0.58 | -0.74 |
Diluted Net EPS (GAAP) | -1.03 | -1.09 | -0.90 | -0.58 | -0.74 |